English
Segment disclosures
Company overviewGyre Therapeutics, Inc.
Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.
Revenue · Reported segment facts
4 dimension combinations 37 retained observations 16 reported periods
Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.
Beijing Continent Pharmaceuticals Co Ltd
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=gyre:BeijingContinentPharmaceuticalsCoLtdMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 113450000 | USD | 20240327 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 102290000 | USD | 20240327 | Open filing evidence |
Gyre
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=gyre:GyreMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 508000 | USD | 20261106 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 2427000 | USD | 20261106 | Open filing evidence |
| 2026-04-01 – 2026-06-30 | 8000 | USD | 20260807 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 1919000 | USD | 20260807 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 0 | USD | 20260508 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 2130000 | USD | 20261106 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 13606000 | USD | 20261106 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 2963000 | USD | 20260807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 11476000 | USD | 20260807 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 0 | USD | 20260508 | Open filing evidence |
Gyre Pharmaceuticals
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=gyre:GyrePharmaceuticalsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 32426000 | USD | 20261106 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 84042000 | USD | 20261106 | Open filing evidence |
| 2026-04-01 – 2026-06-30 | 29097000 | USD | 20260807 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 51616000 | USD | 20260807 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 22519000 | USD | 20260508 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 116588000 | USD | 20260313 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 30564000 | USD | 20261106 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 79393000 | USD | 20261106 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 26771000 | USD | 20260807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 48829000 | USD | 20260807 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 22058000 | USD | 20260508 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 105757000 | USD | 20260313 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 25488000 | USD | 20251107 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 77885000 | USD | 20251107 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 25225000 | USD | 20250811 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 52397000 | USD | 20250811 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 27172000 | USD | 20250509 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 113450000 | USD | 20250317 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 32042000 | USD | 20241113 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 86302000 | USD | 20241113 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 29329000 | USD | 20240813 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 54260000 | USD | 20240813 | Open filing evidence |
| 2023-01-01 – 2023-03-31 | 24931000 | USD | 20240513 | Open filing evidence |
All Other Segments
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=us-gaap:AllOtherSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 0 | USD | 20260508 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 0 | USD | 20260508 | Open filing evidence |